Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial
Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal (Madrid))
Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron)
Tabernero, Josep (Hospital Universitari Vall d'Hebron)
Cervantes, Andrés (Universitat de València)
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid))
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Gil Calle, S. (Hospital Regional Universitario Carlos Haya (Málaga))
Mizuguchi, Hirokazu (Taiho Oncology)
Carrato, Alfredo (Hospital Universitario Ramón y Cajal (Madrid))
Limón, María Luisa (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
García Carbonero, Rocio (Hospital Universitario 12 de Octubre (Madrid))
Universitat Autònoma de Barcelona

Data:	2017
Resum:	TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0. 68 and 0. 48 for OS and PFS, respectively; both P < 0. 001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup. Primary and key secondary endpoints were evaluated in a post hoc analysis of the RECOURSE Spanish subgroup, using univariate and multivariate analyses. Safety and tolerability were reported with descriptive statistics. The RECOURSE Spanish subgroup included 112 patients (mean age 61 years, 62 % male). Median OS was 6. 8 months in the TAS-102 group (n = 80) versus 4. 6 months in the placebo group (n = 32) [HR = 0. 47; 95 % confidence interval (CI): 0. 28-0. 78; P = 0. 0032). Median PFS was 2. 0 months in the TAS-102 group and 1. 7 months in the placebo group (HR = 0. 47; 95 % CI: 0. 30-0. 74; P = 0. 001). Eighty (100 %) TAS-102 versus 31 (96. 9 %) placebo patients had adverse events (AEs). The most common drug-related ≥Grade 3 AE was neutropenia (40 % TAS-102 versus 0 % placebo). There was 1 (1. 3 %) case of febrile neutropenia in the TAS-102 group versus none in the placebo group. In the RECOURSE Spanish subgroup, TAS-102 was associated with significantly improved OS and PFS versus placebo, consistent with the overall RECOURSE population. No new safety signals were identified. NCT01607957.
Drets:	Tots els drets reservats.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	TAS-102 ; Metastatic colorectal cancer ; Trifluridine ; Tipiracil hydrochloride ; Fluoropyrimidine ; Spain
Publicat a:	Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235, ISSN 1699-3055

DOI: 10.1007/s12094-016-1528-7
PMID: 27443414

9 p, 1023.2 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d’Investigació i Innovació Parc Taulí (I3PT)
Articles > Articles de recerca
Articles > Articles publicats